Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Core Insights - Cellectar Biosciences is set to present new data from the Phase 2 CLOVER-WaM study of iopofosine I 131 for treating Waldenstrom's macroglobulinemia at the ASH 2024 conference [1][4] - Iopofosine I 131 is a novel cancer-targeting agent that has not yet received approval for use in any country [2] - The CLOVER-WaM trial focuses on patients with relapsed and refractory WM who have undergone at least two prior therapies [3] Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company dedicated to developing drugs for cancer treatment, utilizing its proprietary Phospholipid Drug Conjugate™ (PDC™) delivery platform [10][11] - The company aims to improve efficacy and safety in cancer treatments by targeting cancer cells more effectively [10] Market Need - Waldenstrom's macroglobulinemia is an incurable B-cell malignancy with limited treatment options, highlighting the urgent need for new therapies [2][7] - Approximately 26,000 individuals in the U.S. are affected by WM, with 1,500–1,900 new diagnoses each year [7] - There is a significant unmet need for FDA-approved treatments, as over 60% of patients currently use non-FDA approved therapies [9] Clinical Study Details - The CLOVER-WaM trial is an international, multicenter, open-label study assessing the efficacy and safety of iopofosine I 131 in previously treated WM patients [3][5] - The presentation at ASH 2024 will be led by Dr. Sikander Ailawadhi from the Mayo Clinic [5] Future Plans - Cellectar plans to submit a New Drug Application to the FDA in the coming months, seeking priority review due to the lack of effective alternatives for WM patients [4]